Doctors News Hubb
Advertisement Banner
  • Home
  • News
  • Healthcare
  • Public Health
  • Paramedic
  • Nursing
  • Contact Us
No Result
View All Result
  • Home
  • News
  • Healthcare
  • Public Health
  • Paramedic
  • Nursing
  • Contact Us
No Result
View All Result
Doctors News Hubb
No Result
View All Result
Home News

Dapagliflozin Reduces Hospitalizations Among Patients With CKD

admin by admin
December 7, 2022
in News


TUESDAY, Dec. 6, 2022 (HealthDay News) — For patients with chronic kidney disease (CKD), dapagliflozin reduces the risk for hospitalization, according to a study published online Dec. 6 in the Annals of Internal Medicine.

Meir Schechter, M.D., from the University of Groningen in the Netherlands, and colleagues determined the effects of dapagliflozin on first hospitalizations and all hospitalizations in a post-hoc analysis of a randomized clinical trial. A total of 4,304 adults with an estimated glomerular filtration rate (eGFR) of 25 to 75 mL/min/1.73 m2 and urinary albumin-creatinine ratio of 200 to 5,000 mg/g, with or without type 2 diabetes, were randomly assigned to receive either dapagliflozin 10 mg once daily or matching placebo.

The researchers identified 2,072 hospitalizations among 1,224 (28.4 percent) participants during a median follow-up of 2.4 years. Dapagliflozin reduced the risk for a first hospitalization and all hospitalizations compared with placebo (hazard ratio, 0.84 and rate ratio, 0.79, respectively). No evidence was seen for the effects of dapagliflozin on first and all hospitalizations varying by baseline presence of type 2 diabetes. The rate of admissions due to cardiac disorders, renal and urinary disorders, metabolism and nutrition disorders, and neoplasms was reduced with dapagliflozin compared with placebo.

“These findings highlight additional benefits of dapagliflozin beyond those seen for cardiovascular and kidney events, all-cause and cause-specific mortality, eGFR slope, and albuminuria and should be considered when evaluating the totality of evidence favoring provision of dapagliflozin to patients with CKD,” the authors write.

The study was funded by AstraZeneca, the manufacturer of dapagliflozin.

Abstract/Full Text (subscription or payment may be required)

Copyright © 2022 HealthDay. All rights reserved.
healthday



Source link

Advertisement Banner
Previous Post

How to Distinguish Respiratory Distress from Failure

Next Post

Julian Flannery, CEO, Summus – The Health Care Blog

Related Posts

News

Unvaccinated status increases risk of long COVID symptoms

January 29, 2023
News

Rezafungin is non-inferior to caspofungin in the treatment of candidemia and invasive candidiasis

January 28, 2023
News

An Analysis of HDL-bound Apolipoproteins in NAFLD Patients with Advanced Liver Fibrosis

January 27, 2023
News

Restrictive, Liberal Fluid Strategies Yield Similar Outcomes for Sepsis-Induced Hypotension

January 26, 2023
News

Mild to Moderate Cerebral Palsy in Young Children Treated with Vibration Therapy

January 25, 2023
News

Serrated Neoplasia Pathway to Colorectal Cancer Reveals Early Immune and Molecular Alterations

January 24, 2023
Next Post

Julian Flannery, CEO, Summus – The Health Care Blog

Recommended

Medical Fiction: Kyle and the Mistake

3 months ago

Black boxes in the operating room could improve teamwork, patient safety

2 months ago

The AMA v. Dobbs. Part 1. – The Health Care Blog

2 months ago

Recommendations Developed for Managing Neuromuscular Blockade

3 weeks ago

Dupilumab Efficacy in Patients with a Type 2 Phenotype with or without Allergic Asthma

3 weeks ago

© 2022 Doctors News Hubb All rights reserved.

Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Privacy Policy and Terms & Conditions.

Navigate Site

  • Home
  • News
  • Healthcare
  • Public Health
  • Paramedic
  • Nursing
  • Contact Us

Newsletter Sign Up.

No Result
View All Result
  • Home
  • News
  • Healthcare
  • Public Health
  • Paramedic
  • Nursing
  • Contact Us

© 2022 Doctors News Hubb All rights reserved.